BRPI1014887A2 - "composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal" - Google Patents

"composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal"

Info

Publication number
BRPI1014887A2
BRPI1014887A2 BRPI1014887A BRPI1014887A BRPI1014887A2 BR PI1014887 A2 BRPI1014887 A2 BR PI1014887A2 BR PI1014887 A BRPI1014887 A BR PI1014887A BR PI1014887 A BRPI1014887 A BR PI1014887A BR PI1014887 A2 BRPI1014887 A2 BR PI1014887A2
Authority
BR
Brazil
Prior art keywords
transmucosal
buccal
pharmaceutical composition
compound providing
nasal dosage
Prior art date
Application number
BRPI1014887A
Other languages
English (en)
Inventor
Calvin John Ross
Original Assignee
Londonpharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0906971.7A external-priority patent/GB2469791B/en
Priority claimed from PCT/GB2009/050415 external-priority patent/WO2010122275A1/en
Application filed by Londonpharma Ltd filed Critical Londonpharma Ltd
Publication of BRPI1014887A2 publication Critical patent/BRPI1014887A2/pt
Publication of BRPI1014887A8 publication Critical patent/BRPI1014887A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI1014887A 2009-04-23 2010-04-23 composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal BRPI1014887A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation
PCT/GB2010/050672 WO2010122356A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin

Publications (2)

Publication Number Publication Date
BRPI1014887A2 true BRPI1014887A2 (pt) 2016-04-19
BRPI1014887A8 BRPI1014887A8 (pt) 2019-02-12

Family

ID=42244197

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014887A BRPI1014887A8 (pt) 2009-04-23 2010-04-23 composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal

Country Status (24)

Country Link
US (4) US20120157518A1 (pt)
EP (1) EP2424523B1 (pt)
JP (1) JP5795760B2 (pt)
CN (1) CN102395362B (pt)
AU (1) AU2010240654C1 (pt)
BR (1) BRPI1014887A8 (pt)
CA (1) CA2756925A1 (pt)
DK (1) DK2424523T3 (pt)
ES (1) ES2390046T3 (pt)
HK (1) HK1164140A1 (pt)
HR (1) HRP20120711T1 (pt)
IL (1) IL215453A (pt)
ME (1) ME02008B (pt)
MX (1) MX2011010961A (pt)
MY (1) MY155646A (pt)
NZ (1) NZ595469A (pt)
PL (1) PL2424523T3 (pt)
PT (1) PT2424523E (pt)
RS (1) RS52430B (pt)
RU (1) RU2501550C2 (pt)
SG (1) SG175162A1 (pt)
SI (1) SI2424523T1 (pt)
WO (1) WO2010122356A1 (pt)
ZA (1) ZA201107088B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
SG175160A1 (en) * 2009-04-23 2011-11-28 Londonpharma Ltd Sublingual pharmaceutical composition comprising a neutral oil
CN105142631A (zh) * 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
WO2016083827A1 (en) 2014-11-27 2016-06-02 Cipla Limited Pharmaceutical composition comprising an artemisinin derivative for nasal or pulmonary delivery
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
CH692321A5 (de) * 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
IL140402A0 (en) * 1998-07-14 2002-02-10 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
AU2003243418B2 (en) * 2002-06-06 2009-02-19 University Of Washington Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20060233895A1 (en) * 2005-04-15 2006-10-19 Brown Paul R Herbal remedy for treating Lyme disease
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
CN100418524C (zh) * 2005-10-26 2008-09-17 重庆医药工业研究院有限责任公司 一种稳定的青蒿素及青蒿素衍生物的药物组合物

Also Published As

Publication number Publication date
AU2010240654A1 (en) 2011-10-20
IL215453A (en) 2014-11-30
US20120157518A1 (en) 2012-06-21
US20160022629A1 (en) 2016-01-28
SG175162A1 (en) 2011-11-28
HRP20120711T1 (hr) 2012-10-31
ES2390046T3 (es) 2012-11-06
RS52430B (en) 2013-02-28
MX2011010961A (es) 2012-04-20
CA2756925A1 (en) 2010-10-28
SI2424523T1 (sl) 2012-11-30
MY155646A (en) 2015-11-13
EP2424523A1 (en) 2012-03-07
RU2011139637A (ru) 2013-05-27
HK1164140A1 (en) 2012-09-21
BRPI1014887A8 (pt) 2019-02-12
EP2424523B1 (en) 2012-06-27
ZA201107088B (en) 2012-12-27
ME02008B (me) 2013-02-28
CN102395362A (zh) 2012-03-28
IL215453A0 (en) 2011-12-29
AU2010240654B2 (en) 2014-05-08
US20170368023A1 (en) 2017-12-28
NZ595469A (en) 2013-10-25
PL2424523T3 (pl) 2012-11-30
PT2424523E (pt) 2012-10-03
US20190142737A1 (en) 2019-05-16
CN102395362B (zh) 2014-07-02
DK2424523T3 (da) 2012-09-24
AU2010240654C1 (en) 2014-08-14
JP2012524772A (ja) 2012-10-18
RU2501550C2 (ru) 2013-12-20
JP5795760B2 (ja) 2015-10-14
WO2010122356A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
IL193727A0 (en) Dosage forms for administering combinations of drugs
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
IL198753A0 (en) Oral transmucosal nicotine dosage form
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
HK1154484A1 (en) Oral dosage composition
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
ZA201004654B (en) Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
AP3542A (en) Anti-malarial pharmaceutical composition
BRPI1014887A2 (pt) "composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal"
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI1007474A2 (pt) formulação para administração por via transmucosa oral de moléculas antálgicas e/ou antiespasmódicos.
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
HK1206267A1 (en) Stabilized picoplatin oral dosage form
ZA200708834B (en) Compositions for oral transmucosal delivery of metformin

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]